Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder

计划入组 5 人 · 首次发布于 2021 年 9 月 5 日

Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)

计划入组 14 人 · 首次发布于 2024 年 1 月 16 日

Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK

计划入组 60 人 · 首次发布于 2025 年 9 月 4 日

TRYP-0082

SOL-410

SOL-802（SOLA Biosciences）

Tryp Therapeutics, Inc.

Canada

Sol-Gel Technologies

Israel

Sol-Ti, Inc.

United States

New Mexico Accelerates Psilocybin Therapy Program Launch to December 2026, New Jersey Approves Hospital-Based Pilot

Sol-Gel Technologies Receives Nasdaq Extension to Regain Compliance

Lipum's SOL-116 Shows Promising Phase I Results for Rheumatoid Arthritis Treatment